Blum CA, et al. – Researchers conducted this randomized trial to determine if cosyntropin testing can predict treatment response to glucocorticoids in community-acquired pneumonia (CAP). They performed 1-μg cosyntropin tests comparing prednisone 50 mg with placebo for 7 days. A total of 326 patients in the prednisone and 309 patients in the placebo groups were assessed. After low-dose cosyntropin testing at a dose of 1 μg, neither baseline nor stimulated cortisol predicted glucocorticoid responsiveness in mild to moderate CAP. Thus, the investigators cautioned that, depending on cortisol values or cosyntropin test results, treatment decisions for or against adjunct glucocorticoids in CAP should not be taken.